# Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects

> **NCT02229773** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIBB 1464 MS low dose
- **DRUG:** Placebo
- **DRUG:** Pravastatin
- **DRUG:** BIBB 1464 MS medium dose
- **DRUG:** BIBB 1464 MS high dose

## Key facts

- **NCT ID:** NCT02229773
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2000-05
- **Final completion:** —
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229773, "Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02229773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*